Sally C. Pipes

Commentary

Feds right to curtail California’s Medicaid scam

On Independence Day, President Trump signed the One Big Beautiful Bill Act, which is projected to reduce enrollment in Medicaid programs throughout the country, including Medi-Cal in California. But Californians should cheer, not jeer, these coverage “losses.” The law will primarily disenroll people who should have never been covered by ...
Commentary

Let’s talk about medical debt

A federal judge this month tossed out a Biden-era rule that would have wiped medical debt from consumers’ credit reports. The decision is a victory for borrowers and lenders alike. The now-defunct rule could have ended up hurting the very low-income individuals it was meant to help. Read the entire ...
Commentary

Trump Must Shut Down Counterfeit Weight-Loss Drugs

Americans looking to lose weight are increasingly turning to the internet. And they’re being duped. Telehealth startups and fly-by-night pharmacies are peddling what look like cheap, convenient versions of blockbuster drugs like Ozempic and Wegovy. But many of these offerings are neither authentic nor safe. They’re “compounded” copies — knockoffs ...
Commentary

The Big Beautiful Bill Fixes One Drug Problem—But Highlights An Even Bigger One

Buried within the One Big Beautiful Bill Act, which President Donald Trump signed into law July 4, is a provision that could improve or even save the lives of the 30 million Americans suffering from rare diseases. That provision is the Orphan Cures Act, which exempts certain drugs that treat ...
Commentary

One Big Beautiful Bill: A Fiscal Lifeline for Medicaid, Taxpayers

The “One Big Beautiful Bill” Act (OBBBA) signed into law by President Donald Trump on July 4 is set to help pull America’s healthcare system back from the brink of fiscal disaster. Read the entire op-ed here.
Commentary

The Culprit Impeding Drug Competition Is Not Who The Feds Expected

The Federal Trade Commission and U.S. Department of Justice recently kicked off a series of listening sessions to examine barriers to competition in the drug industry. The title of the first session—”Anticompetitive Conduct by Pharmaceutical Companies”—made it seem that regulators would chiefly investigate biotech firms. Yet by the end, panelists ...
Commentary

No, Donald Trump didn’t just slash Medicaid

Republicans’ One Big Beautiful Bill Act is now law. Democrats have wasted no time accusing the GOP of enshrining devastating “cuts” to Medicaid, the joint federal-state entitlement that provides health coverage for low-income Americans. That’s rubbish. The measure takes steps to restrain Medicaid’s rampant growth in recent years so that ...
Commentary

Cheap Drugs from Canada Can’t Make America Healthy

The U.S. Food and Drug Administration just announced plans to help states and Indian tribes purchase certain prescription drugs from Canada, where brand-name medicines tend to be cheaper because the government caps their price. The new guidance is part of a larger Trump administration effort to cut drug prices for ...
Commentary

As PBMs Drive Up Drug Prices, Silence Is Not Golden

The Trump administration has been mum in recent weeks on its “most favored nation” drug pricing plan, which broadly aims to link U.S. prices for medicines to the lowest prices in other developed countries. It’s unclear what those prices will be, how they’ll be determined, or how the administration will ...
Commentary

A Promising New AIDS Drug Highlights The Dangers Of Price Controls

The U.S. Food and Drug Administration approved a shot last month that effectively prevents HIV. At-risk people simply need to receive the injection every six months. The new drug, called lenacapavir, comes almost exactly 44 years after the first case of AIDS was reported by what’s now known as the ...
Commentary

Feds right to curtail California’s Medicaid scam

On Independence Day, President Trump signed the One Big Beautiful Bill Act, which is projected to reduce enrollment in Medicaid programs throughout the country, including Medi-Cal in California. But Californians should cheer, not jeer, these coverage “losses.” The law will primarily disenroll people who should have never been covered by ...
Commentary

Let’s talk about medical debt

A federal judge this month tossed out a Biden-era rule that would have wiped medical debt from consumers’ credit reports. The decision is a victory for borrowers and lenders alike. The now-defunct rule could have ended up hurting the very low-income individuals it was meant to help. Read the entire ...
Commentary

Trump Must Shut Down Counterfeit Weight-Loss Drugs

Americans looking to lose weight are increasingly turning to the internet. And they’re being duped. Telehealth startups and fly-by-night pharmacies are peddling what look like cheap, convenient versions of blockbuster drugs like Ozempic and Wegovy. But many of these offerings are neither authentic nor safe. They’re “compounded” copies — knockoffs ...
Commentary

The Big Beautiful Bill Fixes One Drug Problem—But Highlights An Even Bigger One

Buried within the One Big Beautiful Bill Act, which President Donald Trump signed into law July 4, is a provision that could improve or even save the lives of the 30 million Americans suffering from rare diseases. That provision is the Orphan Cures Act, which exempts certain drugs that treat ...
Commentary

One Big Beautiful Bill: A Fiscal Lifeline for Medicaid, Taxpayers

The “One Big Beautiful Bill” Act (OBBBA) signed into law by President Donald Trump on July 4 is set to help pull America’s healthcare system back from the brink of fiscal disaster. Read the entire op-ed here.
Commentary

The Culprit Impeding Drug Competition Is Not Who The Feds Expected

The Federal Trade Commission and U.S. Department of Justice recently kicked off a series of listening sessions to examine barriers to competition in the drug industry. The title of the first session—”Anticompetitive Conduct by Pharmaceutical Companies”—made it seem that regulators would chiefly investigate biotech firms. Yet by the end, panelists ...
Commentary

No, Donald Trump didn’t just slash Medicaid

Republicans’ One Big Beautiful Bill Act is now law. Democrats have wasted no time accusing the GOP of enshrining devastating “cuts” to Medicaid, the joint federal-state entitlement that provides health coverage for low-income Americans. That’s rubbish. The measure takes steps to restrain Medicaid’s rampant growth in recent years so that ...
Commentary

Cheap Drugs from Canada Can’t Make America Healthy

The U.S. Food and Drug Administration just announced plans to help states and Indian tribes purchase certain prescription drugs from Canada, where brand-name medicines tend to be cheaper because the government caps their price. The new guidance is part of a larger Trump administration effort to cut drug prices for ...
Commentary

As PBMs Drive Up Drug Prices, Silence Is Not Golden

The Trump administration has been mum in recent weeks on its “most favored nation” drug pricing plan, which broadly aims to link U.S. prices for medicines to the lowest prices in other developed countries. It’s unclear what those prices will be, how they’ll be determined, or how the administration will ...
Commentary

A Promising New AIDS Drug Highlights The Dangers Of Price Controls

The U.S. Food and Drug Administration approved a shot last month that effectively prevents HIV. At-risk people simply need to receive the injection every six months. The new drug, called lenacapavir, comes almost exactly 44 years after the first case of AIDS was reported by what’s now known as the ...
Scroll to Top